Inotek Pharmaceuticals Corporation - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Inotek Pharmaceuticals Corporation - Product Pipeline Review - 2013 which provides data on the Inotek Pharmaceuticals Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Inotek Pharmaceuticals Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Inotek Pharmaceuticals Corporation and industry-specific third party sources, put together by team of industry experts.

Scope

- Inotek Pharmaceuticals Corporation - Brief Inotek Pharmaceuticals Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Inotek Pharmaceuticals Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Inotek Pharmaceuticals Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Inotek Pharmaceuticals Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Inotek Pharmaceuticals Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Inotek Pharmaceuticals Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Inotek Pharmaceuticals Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Inotek Pharmaceuticals Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Inotek Pharmaceuticals Corporation and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Inotek Pharmaceuticals Corporation - Product Pipeline Review - 2013.

Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2013 which provides data on the Tekmira Pharmaceuticals Corp.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Tekmira Pharmaceuticals Corp.’s corporate website, SEC filings, investor presentations and featured press releases, both from Tekmira Pharmaceuticals Corp. and industry-specific third party sources, put together by team of industry experts.

Scope

- Tekmira Pharmaceuticals Corp. - Brief Tekmira Pharmaceuticals Corp. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Tekmira Pharmaceuticals Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Tekmira Pharmaceuticals Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Tekmira Pharmaceuticals Corp.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Tekmira Pharmaceuticals Corp.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Tekmira Pharmaceuticals Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Tekmira Pharmaceuticals Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Tekmira Pharmaceuticals Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Tekmira Pharmaceuticals Corp. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2013.

Orexo AB - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Orexo AB - Product Pipeline Review - 2013 which provides data on the Orexo AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Orexo AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Orexo AB and industry-specific third party sources, put together by team of industry experts.

Scope

- Orexo AB - Brief Orexo AB overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Orexo AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Orexo AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Orexo AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Orexo AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Orexo AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Orexo AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Orexo AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Orexo AB and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Orexo AB - Product Pipeline Review - 2013.

Charlesson LLC. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Charlesson LLC. - Product Pipeline Review - 2013 which provides data on the Charlesson LLC.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Charlesson LLC.’s corporate website, SEC filings, investor presentations and featured press releases, both from Charlesson LLC. and industry-specific third party sources, put together by team of industry experts.

Scope

- Charlesson LLC. - Brief Charlesson LLC. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Charlesson LLC. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Charlesson LLC. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Charlesson LLC.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Charlesson LLC.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Charlesson LLC. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Charlesson LLC.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Charlesson LLC..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Charlesson LLC. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Charlesson LLC. - Product Pipeline Review - 2013.

Neurotune AG - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Neurotune AG - Product Pipeline Review - 2013 which provides data on the Neurotune AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Neurotune AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Neurotune AG and industry-specific third party sources, put together by team of industry experts.

Scope

- Neurotune AG - Brief Neurotune AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Neurotune AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Neurotune AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Neurotune AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Neurotune AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Neurotune AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Neurotune AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Neurotune AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Neurotune AG and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Neurotune AG - Product Pipeline Review - 2013.

Ambrx, Inc. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Ambrx, Inc. - Product Pipeline Review - 2013 which provides data on the Ambrx, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Ambrx, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ambrx, Inc. and industry-specific third party sources, put together by team of industry experts.

Scope

- Ambrx, Inc. - Brief Ambrx, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ambrx, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ambrx, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ambrx, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Ambrx, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ambrx, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ambrx, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ambrx, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ambrx, Inc. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Ambrx, Inc. - Product Pipeline Review - 2013.

Foamix Ltd. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Foamix Ltd. - Product Pipeline Review - 2013 which provides data on the Foamix Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Foamix Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Foamix Ltd. and industry-specific third party sources, put together by team of industry experts.

Scope

- Foamix Ltd. - Brief Foamix Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Foamix Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Foamix Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Foamix Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Foamix Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Foamix Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Foamix Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Foamix Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Foamix Ltd. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Foamix Ltd. - Product Pipeline Review - 2013.

Synta Pharmaceuticals Corp. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Synta Pharmaceuticals Corp. - Product Pipeline Review - 2013 which provides data on the Synta Pharmaceuticals Corp.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Synta Pharmaceuticals Corp.’s corporate website, SEC filings, investor presentations and featured press releases, both from Synta Pharmaceuticals Corp. and industry-specific third party sources, put together by team of industry experts.

Scope

- Synta Pharmaceuticals Corp. - Brief Synta Pharmaceuticals Corp. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Synta Pharmaceuticals Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Synta Pharmaceuticals Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Synta Pharmaceuticals Corp.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Synta Pharmaceuticals Corp.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Synta Pharmaceuticals Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Synta Pharmaceuticals Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Synta Pharmaceuticals Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Synta Pharmaceuticals Corp. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Synta Pharmaceuticals Corp. - Product Pipeline Review - 2013.

Yakult Honsha Co., Ltd. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Yakult Honsha Co., Ltd. - Product Pipeline Review - 2013 which provides data on the Yakult Honsha Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Yakult Honsha Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Yakult Honsha Co., Ltd. and industry-specific third party sources, put together by team of industry experts.

Scope

- Yakult Honsha Co., Ltd. - Brief Yakult Honsha Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Yakult Honsha Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Yakult Honsha Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Yakult Honsha Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Yakult Honsha Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Yakult Honsha Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Yakult Honsha Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Yakult Honsha Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Yakult Honsha Co., Ltd. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Yakult Honsha Co., Ltd. - Product Pipeline Review - 2013.

EyeGene, Inc. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on EyeGene, Inc. - Product Pipeline Review - 2013 which provides data on the EyeGene, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, EyeGene, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from EyeGene, Inc. and industry-specific third party sources, put together by team of industry experts.

Scope

- EyeGene, Inc. - Brief EyeGene, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of EyeGene, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of EyeGene, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the EyeGene, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate EyeGene, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of EyeGene, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the EyeGene, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with EyeGene, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of EyeGene, Inc. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit EyeGene, Inc. - Product Pipeline Review - 2013.

Helix BioMedix, Inc. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Helix BioMedix, Inc. - Product Pipeline Review - 2013 which provides data on the Helix BioMedix, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Helix BioMedix, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Helix BioMedix, Inc. and industry-specific third party sources, put together by team of industry experts.

Scope

- Helix BioMedix, Inc. - Brief Helix BioMedix, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Helix BioMedix, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Helix BioMedix, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Helix BioMedix, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Helix BioMedix, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Helix BioMedix, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Helix BioMedix, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Helix BioMedix, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Helix BioMedix, Inc. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Helix BioMedix, Inc. - Product Pipeline Review - 2013

ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013 which provides data on the ImmunoCellular Therapeutics, Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, ImmunoCellular Therapeutics, Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from ImmunoCellular Therapeutics, Ltd. and industry-specific third party sources, put together by team of industry experts.

Scope

- ImmunoCellular Therapeutics, Ltd. - Brief ImmunoCellular Therapeutics, Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ImmunoCellular Therapeutics, Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ImmunoCellular Therapeutics, Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ImmunoCellular Therapeutics, Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ImmunoCellular Therapeutics, Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ImmunoCellular Therapeutics, Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ImmunoCellular Therapeutics, Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ImmunoCellular Therapeutics, Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ImmunoCellular Therapeutics, Ltd. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013.

NeurAxon, Inc. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on NeurAxon, Inc. - Product Pipeline Review - 2013 which provides data on the NeurAxon, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, NeurAxon, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from NeurAxon, Inc. and industry-specific third party sources, put together by team of industry experts.

Scope

- NeurAxon, Inc. - Brief NeurAxon, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of NeurAxon, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of NeurAxon, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the NeurAxon, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate NeurAxon, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of NeurAxon, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the NeurAxon, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with NeurAxon, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of NeurAxon, Inc. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit NeurAxon, Inc. - Product Pipeline Review - 2013.

Oncodesign SA - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Oncodesign SA - Product Pipeline Review - 2013 which provides data on the Oncodesign SA’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Oncodesign SA’s corporate website, SEC filings, investor presentations and featured press releases, both from Oncodesign SA and industry-specific third party sources, put together by team of industry experts.

Scope

- Oncodesign SA - Brief Oncodesign SA overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oncodesign SA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Oncodesign SA with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Oncodesign SA’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Oncodesign SA’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Oncodesign SA in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Oncodesign SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Oncodesign SA.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Oncodesign SA and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Oncodesign SA - Product Pipeline Review - 2013

Adocia - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Adocia - Product Pipeline Review - 2013 which provides data on the Adocia’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Adocia’s corporate website, SEC filings, investor presentations and featured press releases, both from Adocia and industry-specific third party sources, put together by team of industry experts.

Scope

- Adocia - Brief Adocia overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Adocia human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Adocia with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Adocia’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Adocia’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Adocia in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Adocia’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Adocia.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Adocia and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Adocia - Product Pipeline Review - 2013

GeneScience Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on GeneScience Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2013 which provides data on the GeneScience Pharmaceuticals Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, GeneScience Pharmaceuticals Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from GeneScience Pharmaceuticals Co., Ltd. and industry-specific third party sources, put together by team of industry experts.

Scope

- GeneScience Pharmaceuticals Co., Ltd. - Brief GeneScience Pharmaceuticals Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of GeneScience Pharmaceuticals Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of GeneScience Pharmaceuticals Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the GeneScience Pharmaceuticals Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate GeneScience Pharmaceuticals Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of GeneScience Pharmaceuticals Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the GeneScience Pharmaceuticals Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with GeneScience Pharmaceuticals Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of GeneScience Pharmaceuticals Co., Ltd. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit GeneScience Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2013.

Laboratorios Del Dr. Esteve S.A. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Laboratorios Del Dr. Esteve S.A. - Product Pipeline Review - 2013 which provides data on the Laboratorios Del Dr. Esteve S.A.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Laboratorios Del Dr. Esteve S.A.’s corporate website, SEC filings, investor presentations and featured press releases, both from Laboratorios Del Dr. Esteve S.A. and industry-specific third party sources, put together by team of industry experts.

Scope

- Laboratorios Del Dr. Esteve S.A. - Brief Laboratorios Del Dr. Esteve S.A. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Laboratorios Del Dr. Esteve S.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Laboratorios Del Dr. Esteve S.A. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Laboratorios Del Dr. Esteve S.A.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Laboratorios Del Dr. Esteve S.A.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Laboratorios Del Dr. Esteve S.A. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Laboratorios Del Dr. Esteve S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Laboratorios Del Dr. Esteve S.A..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Laboratorios Del Dr. Esteve S.A. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Laboratorios Del Dr. Esteve S.A. - Product Pipeline Review - 2013.

Applied Genetic Technologies Corporation - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Applied Genetic Technologies Corporation - Product Pipeline Review - 2013 which provides data on the Applied Genetic Technologies Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Applied Genetic Technologies Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Applied Genetic Technologies Corporation and industry-specific third party sources, put together by team of industry experts.

Scope

- Applied Genetic Technologies Corporation - Brief Applied Genetic Technologies Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Applied Genetic Technologies Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Applied Genetic Technologies Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Applied Genetic Technologies Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Applied Genetic Technologies Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Applied Genetic Technologies Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Applied Genetic Technologies Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Applied Genetic Technologies Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Applied Genetic Technologies Corporation and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Applied Genetic Technologies Corporation - Product Pipeline Review - 2013.

Jennerex Biotherapeutics, Inc. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Jennerex Biotherapeutics, Inc. - Product Pipeline Review - 2013 which provides data on the Jennerex Biotherapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Jennerex Biotherapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Jennerex Biotherapeutics, Inc. and industry-specific third party sources, put together by team of industry experts.

Scope

- Jennerex Biotherapeutics, Inc. - Brief Jennerex Biotherapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Jennerex Biotherapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Jennerex Biotherapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Jennerex Biotherapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Jennerex Biotherapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Jennerex Biotherapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Jennerex Biotherapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Jennerex Biotherapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Jennerex Biotherapeutics, Inc. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Jennerex Biotherapeutics, Inc. - Product Pipeline Review - 2013.

DEKK-TEC, Inc. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on DEKK-TEC, Inc. - Product Pipeline Review - 2013 which provides data on the DEKK-TEC, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, DEKK-TEC, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from DEKK-TEC, Inc. and industry-specific third party sources, put together by team of industry experts.

Scope

- DEKK-TEC, Inc. - Brief DEKK-TEC, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of DEKK-TEC, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of DEKK-TEC, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the DEKK-TEC, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate DEKK-TEC, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of DEKK-TEC, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the DEKK-TEC, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with DEKK-TEC, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of DEKK-TEC, Inc. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit DEKK-TEC, Inc. - Product Pipeline Review - 2013.

Insight Report: Philanthropy

Reportstack has announced a new market research publication on Insight Report: Philanthropy. The report provides market analysis and insights, including:
• In-depth analysis of the philanthropic sector and the opportunities and challenges it holds for wealth management firms
• Detailed analysis of key causes that attract the attention of HNWIs for philanthropic contributions
• Detailed analysis of key and emerging trends in the philanthropic sector
• Insights into the philanthropic giving patterns of HNWIs across regions
• Case studies of private banks and wealth managers that are successfully challenging the sector’s dynamics

Summary

Global philanthropic activity demonstrated steady growth during the review period, and HNWIs have played a significant role in achieving this. However, the global trend of giving among HNWIs varies by region and country, depending on demographics, culture and traditions. Accordingly, each region has its own drivers and challenges. While a decline is being observed in spontaneous HNWI contributions in the philanthropy sector, structured philanthropic contributions are growing. Rather than contributing to qualify for tax deductions, the focus of HNWIs has increasingly been concentrated around the impact of their philanthropic investments. Many HNWIs are willing to become actively involved in their cause by volunteering. The philanthropy sector is demonstrating an increasing focus on impact and innovation.

Scope

• This report provides an in-depth analysis of the philanthropic sector and the opportunities it holds for wealth management firms. It includes case studies of private banks and wealth managers that are successfully challenging the sector’s dynamics.
• The report focuses on the philanthropic trends of HNWIs worldwide, and provides analysis from proprietary HNWI database comprising over 75,000 individuals. For the purpose of identifying regional trends, HNWI philanthropists have been segmented by the geographical region.
• The report examines the specific trends in the Americas, Europe, Asia-Pacific, the Middle East and Africa. For each region, the motives of HNWI philanthropists are analyzed by age, gender, the industry they belong to, and their wealth band.


Reasons To Buy

• Take strategic business decisions using information on the involvement of HNWIs in philanthropic activities across different regions.
• Understand the factors that affect HNWIs' philanthropic decision-making processes.
• Understand current strategic offerings of wealth management firms to attract HNWI philanthropists.
• Understand the role played by charitable organizations and giving vehicles in the philanthropy sector.

Key Highlights

• The US is the largest philanthropic market in the world, followed by Europe and Asia-Pacific.
• The global philanthropic sector is changing in terms of processes and approach, as HNWIs’ contributions become more impact-oriented.
• China and India are expected to play important roles in the philanthropy market over the forecast period.
• Micro-finance and venture philanthropy are spreading among HNWIs.
• Low numbers of family offices in emerging markets are negating the impact of philanthropy.

Companies Mentioned

• Coutts Private Bank
• Barclay's Private Banking
• Biocon India Ltd
• Narayana Hrudayalaya
• St James's Place
• Credit Suisse
• Fine Art Wealth Management
• Wellcome Trust
• The Gatsby Charitable Foundation
• Garfield Weston Foundation
• The Leverhulme Trust
• Esmée Fairbairn Foundation
• Bertelsmann Stiftung
• Stichting INGKA Foundation
• Robert Bosch Stiftung GmbH
• Fondazione Giorgio Cini
• FondazionePierfranco e Luisa MarianiOnlus
• Fundacion Pedro Barrie de la Maza
• JLFondet
• CalousteGulbenkian Foundation

To view the table of contents and know more details please visit Insight Report: Philanthropy.

Global and China FPCB(Flexible Printed Circuit Board)Industry Report,2013-2014

Reportstack has announced a new market research publication on Global and China FPCB(Flexible Printed Circuit Board)Industry Report,2013-2014 . The global FPCB market valued USD11.321 billion with the YoY growth rate of 9.4% in 2013, and will be worth USD12.008 billion in 2014 and USD12.686 billion in 2015.

FPCB is mainly used in display (LCD Panel and Touch screen), computing (HDD and ODD) and communication (mobile phones). In 2013, the FPCB applied to the computer field occupied 25%, of which 80% was dominated by Japanese companiess; however, this market is gradually shrinking.

In the field of mobile phones and tablet PCs, only the vendors such as Samsung, Apple, LG, Sony, HTC and Nokia who have high quality requirements like to adopt FPCB, while other ones may replace FPCB with FFC or common connectors. The FPCB purchase amount of Samsung and Apple is equivalent to over 50% of the global FPCB market.

In 2013, the most significant change of the FPCB industry lied in the slumping profit margin of veterans and the soaring profit margin of new entrants. Veterans lagged behind new entrants in equipment and technical R & D strength. After a high starting point and early difficulties, new entrants witnessed a significant increase in profit margin. In addition, the production bases of veterans were mostly located in Mainland China, where RMB appreciation and rising labor costs led to the substantial fall of profits.

The world's largest FPCB company Mektron suffered its first loss since the establishment, because of three main reasons: First, HDD and ODD markets contracted; second, Mektron began to intervene in the price war; third, Mektron’s 45% output came from China where RMB appreciation and rising labor costs eroded profits. Mektron has increased the capacity in Taiwan, and Panasonic has also invested USD100 million in building a new FPCB base in Taiwan.

The gross margin of South Korea's largest FPCB company Interflex fell by nearly 50% in 2013, and its operating margin plummeted from 6.2% to 1.2%. The only FPCB company in the United States ------ MFLEX whose manufacturing bases were in Mainland China also faced loss for the first time. Fast-growing companies such as Flexcom and BHflex transferred their main production bases to Vietnam.

Hon Hai Group's ZDT obtained more orders from Apple with the advantages of the parent company, so that its profit margin went up substantially. ZDT's main base is located in Shenzhen, but it has also transferred part of its bases to low-cost regions: its second base settles down in Qinhuangdao, and the third base is in Huai'an.

To view the table of contents and know more details please visit Global and China FPCB(Flexible Printed Circuit Board)Industry Report,2013-2014.

Immunotope, Inc. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Immunotope, Inc. - Product Pipeline Review - 2013 which provides data on the Immunotope, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Immunotope, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Immunotope, Inc. and industry-specific third party sources, put together by team of industry experts.

Scope

- Immunotope, Inc. - Brief Immunotope, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Immunotope, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Immunotope, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Immunotope, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Immunotope, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Immunotope, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Immunotope, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Immunotope, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Immunotope, Inc. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Immunotope, Inc. - Product Pipeline Review - 2013.

SBI Biotech Co., Ltd. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on SBI Biotech Co., Ltd. - Product Pipeline Review - 2013 which provides data on the SBI Biotech Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from roprietary databases, SBI Biotech Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from SBI Biotech Co., Ltd. and industry-specific third party sources, put together by team of industry experts.

Scope

- SBI Biotech Co., Ltd. - Brief SBI Biotech Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of SBI Biotech Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of SBI Biotech Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the SBI Biotech Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate SBI Biotech Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of SBI Biotech Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the SBI Biotech Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with SBI Biotech Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of SBI Biotech Co., Ltd. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit SBI Biotech Co., Ltd. - Product Pipeline Review - 2013.

Trophogen, Inc. - Product Pipeline Review - 2013

Reportstack has announced a new market research publication on Trophogen, Inc. - Product Pipeline Review - 2013 which provides data on the Trophogen, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Trophogen, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Trophogen, Inc. and industry-specific third party sources, put together by team of industry experts.

Scope

- Trophogen, Inc. - Brief Trophogen, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Trophogen, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Trophogen, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Trophogen, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Trophogen, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Trophogen, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Trophogen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Trophogen, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Trophogen, Inc. and identify potential opportunities in those areas.

To view the table of contents and know more details please visit Trophogen, Inc. - Product Pipeline Review - 2013.